{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:49Z","timestamp":1790375989765,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijd.ijd_73_17","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T08:17:23Z","timestamp":1488961043000},"page":"142","source":"Crossref","is-referenced-by-count":13,"title":["New targeted treatments for cutaneous T-cell Lymphomas"],"prefix":"10.4103","volume":"62","author":[{"given":"Martine","family":"Bagot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-5154.201771-1","first-page":"1713","volume-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"key-10.4103\/0019-5154.201771-2","first-page":"472","volume-title":"Multilineage progression of genetically unstable tumor subclones in cutaneous T-cell lymphoma","author":"R\u00fcbben","year":"2004","journal-title":"Exp Dermatol"},{"key":"key-10.4103\/0019-5154.201771-3","first-page":"4267","volume-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0019-5154.201771-4","first-page":"250","volume-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"key-10.4103\/0019-5154.201771-5","first-page":"1969","volume-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: A single institution experience from the Robert H.Lurie Comprehensive Cancer Center","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0019-5154.201771-6","first-page":"784","volume-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: Clinical and immunologic findings in 14 patients","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"key-10.4103\/0019-5154.201771-7","first-page":"720","volume-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","author":"de","year":"2014","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0019-5154.201771-8","first-page":"1236","volume-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"key-10.4103\/0019-5154.201771-9","first-page":"2190","volume-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-5154.201771-10","first-page":"3750","volume-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: A multi-institution collaborative project","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-5154.201771-11","first-page":"3759","volume-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-5154.201771-12","first-page":"1591","volume-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-5154.201771-13","first-page":"1883","volume-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"key-10.4103\/0019-5154.201771-14","first-page":"1157","volume-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-5154.201771-15","first-page":"606","volume-title":"Stevens-Johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an adult T-cell leukaemia patient","author":"Honda","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/0019-5154.201771-16","first-page":"274","volume-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0019-5154.201771-17","first-page":"1388","volume-title":"CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor","author":"Bagot","year":"2001","journal-title":"Blood"},{"key":"key-10.4103\/0019-5154.201771-18","first-page":"77","volume-title":"Killer cell immunoglobulin-like receptor expression delineates in situ S\u00e9zary syndrome lymphocytes","author":"Wechsler","year":"2003","journal-title":"J Pathol"},{"key":"key-10.4103\/0019-5154.201771-19","first-page":"820","volume-title":"CD158k\/KIR3DL2 is a new phenotypic marker of Sezary cells: Relevance for the diagnosis and follow-up of Sezary syndrome","author":"Poszepczynska-Guign\u00e9","year":"2004","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0019-5154.201771-20","first-page":"156","volume-title":"CD158k\/KIR3DL2 is a useful marker for identifying neoplastic T-cells in S\u00e9zary syndrome by flow cytometry","author":"Bahler","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"key-10.4103\/0019-5154.201771-21","first-page":"461","volume-title":"CD158k\/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides","author":"Ortonne","year":"2012","journal-title":"Exp Dermatol"},{"key":"key-10.4103\/0019-5154.201771-22","first-page":"247","volume-title":"CD158k is a reliable marker for diagnosis of S\u00e9zary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","author":"Moins-Teisserenc","year":"2015","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/0019-5154.201771-23","first-page":"6060","volume-title":"IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma","author":"Marie-Cardine","year":"2014","journal-title":"Cancer Res"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:28:50Z","timestamp":1786714130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_73_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"alternative-id":["201771"],"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_73_17","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}